Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor ...

The dangerous drug can give users a more powerful high, but high doses can cause the heart to slow and fail, leading to ...

Merck & Co. agrees to acquire Eyebiotech (EyeBio) for up to $3 billion, a deal that will return the buyer to the eye drug ...

Driven by growing market demand and an improving supply chain, the global weight-loss drug market is expected to hit $150 ...

Merck & Co. is focusing in on eye diseases with the $3 billion acquisition of ophthalmology-focused Eyebiotech. | Merck & Co.

About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a ...

For the past year and a half, Tandra Cooper Harris and her husband, Marcus, who both have diabetes, have struggled to fill ...

ANV600 combines a non-blocking αPD-1 antibody and an IL-2Rβ/γ selective agonist targeting IL-2 to tumor-specific T cells resulting in ...

Altimmune is developing pemvidutide, a dual agonist of GLP-1 and glucagon receptors, with promising phase 2 data already seen ...

NRBO READ THE FULL NRBO RESEARCH REPORT Business Update Pre-Clinical MASH Data for DA-1241 to be Presented at EASL Congress ...

With back-to-back victories in IgA nephropathy and C3 glomerulopathy, Novartis on Saturday said it is planning to make ...